Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

肾细胞癌疾病进展过程中免疫功能逐渐减弱

阅读:3
作者:David A Braun ,Kelly Street ,Kelly P Burke ,David L Cookmeyer ,Thomas Denize ,Christina B Pedersen ,Satyen H Gohil ,Nicholas Schindler ,Lucas Pomerance ,Laure Hirsch ,Ziad Bakouny ,Yue Hou ,Juliet Forman ,Teddy Huang ,Shuqiang Li ,Ang Cui ,Derin B Keskin ,John Steinharter ,Gabrielle Bouchard ,Maxine Sun ,Erica M Pimenta ,Wenxin Xu ,Kathleen M Mahoney ,Bradley A McGregor ,Michelle S Hirsch ,Steven L Chang ,Kenneth J Livak ,David F McDermott ,Sachet A Shukla ,Lars R Olsen ,Sabina Signoretti ,Arlene H Sharpe ,Rafael A Irizarry ,Toni K Choueiri ,Catherine J Wu

Abstract

The tumor immune microenvironment plays a critical role in cancer progression and response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the composition and phenotypic states of immune cells in this tumor are incompletely characterized. We performed single-cell RNA and T cell receptor sequencing on 164,722 individual cells from tumor and adjacent non-tumor tissue in patients with ccRCC across disease stages: early, locally advanced, and advanced/metastatic. Terminally exhausted CD8+ T cells were enriched in metastatic disease and were restricted in T cell receptor diversity. Within the myeloid compartment, pro-inflammatory macrophages were decreased, and suppressive M2-like macrophages were increased in advanced disease. Terminally exhausted CD8+ T cells and M2-like macrophages co-occurred in advanced disease and expressed ligands and receptors that support T cell dysfunction and M2-like polarization. This immune dysfunction circuit is associated with a worse prognosis in external cohorts and identifies potentially targetable immune inhibitory pathways in ccRCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。